medica 16 has been researched along with Hyperlipidemias in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atkinson, LL; Bar-Tana, J; Kelly, SE; Lopaschuk, GD; Russell, JC | 1 |
| Adler, JH; Bar-Tana, J; Rose-Kahn, G; Tzur, R | 1 |
2 other study(ies) available for medica 16 and Hyperlipidemias
| Article | Year |
|---|---|
MEDICA 16 inhibits hepatic acetyl-CoA carboxylase and reduces plasma triacylglycerol levels in insulin-resistant JCR: LA-cp rats.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Hyperinsulinism; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Liver; Multienzyme Complexes; Muscle, Skeletal; Obesity; Palmitic Acids; Protein Serine-Threonine Kinases; Rats; Rats, Mutant Strains; Triglycerides | 2002 |
Hypolipidemic, antiobesity, and hypoglycemic-hypoinsulinemic effects of beta,beta'-methyl-substituted hexadecanedioic acid in sand rats.
Topics: Adipose Tissue; Animals; Arvicolinae; Blood Glucose; Diabetes Mellitus, Experimental; Hyperglycemia; Hyperlipidemias; Insulin; Male; Obesity; Palmitic Acids; Receptor, Insulin | 1988 |